Scand J Urol Nephrol 25: 233-236, 1991
REDUCTION IN SERUM ALKALINE PHOSPHATASE LEVELS BY TREATMENT WITH ACTIVE VITAMIN D (ALPHACALCIDOL) IN PRIMARY AND SECONDARY HYPERPARATHYROIDISM AND IN EUPARATHYROID INDIVIDUALS L. Lind, B. Wengle, H. Lithell and S. Ljunghall From the Departments of Internal Medicine and Geriatrics, Uppsala University Hospital. Uppsala and Department of Internal Medicine, Gavle County Hospital, Gavle, Sweden Scand J Urol Nephrol Downloaded from informahealthcare.com by University of Newcastle on 12/31/14 For personal use only.
(Submitted August 9, 1990. Accepted for publication August 29, 1990)
Abstract. Raised levels of alkaline phospatases (ALP) are seen in conditions with a high bone turn-over, such as in primary and secondary hyperparathyroidism (HPT). To study the effects of active vitamin D treatment on ALP, alphacalcidol (1-alpha-hydroxy-vitaminD3),was given to patients with primary HPT as well as HPT secondary to chronic renal failure and also to healthy, euparathyroid subjects. Oral alphacalcidol ( I pg daily) significantly reduced Serum ALP (3.2* 1.1 to 2.82 1.2 Vkatfl, P
REDUCTION IN SERUM ALKALINE PHOSPHATASE LEVELS BY TREATMENT WITH ACTIVE VITAMIN D (ALPHACALCIDOL) IN PRIMARY AND SECONDARY HYPERPARATHYROIDISM AND IN EUPARATHYROID INDIVIDUALS L. Lind, B. Wengle, H. Lithell and S. Ljunghall From the Departments of Internal Medicine and Geriatrics, Uppsala University Hospital. Uppsala and Department of Internal Medicine, Gavle County Hospital, Gavle, Sweden Scand J Urol Nephrol Downloaded from informahealthcare.com by University of Newcastle on 12/31/14 For personal use only.
(Submitted August 9, 1990. Accepted for publication August 29, 1990)
Abstract. Raised levels of alkaline phospatases (ALP) are seen in conditions with a high bone turn-over, such as in primary and secondary hyperparathyroidism (HPT). To study the effects of active vitamin D treatment on ALP, alphacalcidol (1-alpha-hydroxy-vitaminD3),was given to patients with primary HPT as well as HPT secondary to chronic renal failure and also to healthy, euparathyroid subjects. Oral alphacalcidol ( I pg daily) significantly reduced Serum ALP (3.2* 1.1 to 2.82 1.2 Vkatfl, P
